Biotech News
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
SEATTLE, WA / ACCESS Newswire / November 11, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that the Company has entered into warrant inducement letter
